HAEMOLYTIC ANAEMIA AS A COMPLICATION OF INTRAVENOUS IMMUNOGLOBULIN THERAPY

Sharfaraz Salam, Amanda Woodall, David Gosal. Salford Royal NHS Foundation Trust

10.1136/jnnp-2016-315106.187

Aim To monitor a series of thirty consecutive patients receiving their first dose of intravenous immunoglobulin for haemolytic anaemia.

Methods Prospectively, thirty consecutive patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) receiving their first high dose of immunoglobulin therapy were monitored for clinical and laboratory features of haemolytic anaemia.

Results Three patients were identified with features suggestive for haemolysis.

Conclusion We confirm the literature findings of a strong association between high dose intravenous immunoglobulin therapy and haemolysis in neurology patients receiving immunoglobulin therapy.
HAEMOLYTIC ANAEMIA AS A COMPLICATION OF INTRAVENOUS IMMUNOGLOBULIN THERAPY
Sharfaraz Salam, Amanda Woodall and David Gosal

J Neurol Neurosurg Psychiatry 2016 87: e1
doi: 10.1136/jnnp-2016-315106.187

Updated information and services can be found at:
http://jnnp.bmj.com/content/87/12/e1.98

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (1943)
- Neuromuscular disease (1311)
- Peripheral nerve disease (631)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/